U.S. Markets closed

Boehringer unit that makes Johnson & Johnson Doxil to shut, WSJ says

Boehringer Ingelheim's unit that manufactures Johnson & Johnson's cancer drug Doxil is planning to shut down starting this month, reports The Wall Street Journal. The report says Johnson & Johnson is in talks with Ohio-based Ben Venue to ensure Doxil supplies into next year.